2CD0

STRUCTURE OF HUMAN LAMBDA-6 LIGHT CHAIN DIMER WIL

PDB DOI: 10.2210/pdb2CD0/pdb

Classification: IMMUNE SYSTEM
Organism(s): Homo sapiens
Expression System: Escherichia coli
Mutation(s): No

Deposited: 1999-03-08 Released: 2000-03-08
Deposition Author(s): Pokkuluri, P.R., Solomon, A., Weiss, D.T., Stevens, F.J., Schiffer, M.

Experimental Data Snapshot

Method: X-RAY DIFFRACTION
Resolution: 1.80 Å
R-Value Free: 0.351
R-Value Work: 0.289

wwPDB Validation 3D Report Full Report

This is version 1.2 of the entry. See complete history.

Literature

Tertiary structure of human lambda 6 light chains.

Pokkuluri, P.R., Solomon, A., Weiss, D.T., Stevens, F.J., Schiffer, M.

(1999) Amyloid 6: 165-171

PubMed: 10524280 Search on PubMed
DOI: 10.3109/13506129909007322
Primary Citation of Related Structures:
1CD0, 2CD0

PubMed Abstract:

AL amyloidosis is a disease process characterized by the pathologic deposition of monoclonal light chains in tissue. To date, only limited information has been obtained on the molecular features that render such light chains amyloidogenic. Although protein products of the major human V kappa and V lambda gene families have been identified in AL deposits, one particular subgroup--lambda 6--has been found to be preferentially associated with this disease. Notably, the variable region of lambda 6 proteins (V lambda 6) has distinctive primary structural features including the presence in the third framework region (FR3) of two additional amino acid residues that distinguish members of this subgroup from other types of light chains. However, the structural consequences of these alterations have not been elucidated. To determine if lambda 6 proteins possess unique tertiary structural features, as compared to light chains of other V lambda subgroups, we have obtained x-ray diffraction data on crystals prepared from two recombinant V lambda 6 molecules. These components, isolated from a bacterial expression system, were generated from lambda 6-related cDNAs cloned from bone marrow-derived plasma cells from a patient (Wil) who had documented AL amyloidosis and another (Jto) with multiple myeloma and tubular cast nephropathy, but no evident fibrillar deposits. The x-ray crystallographic analyses revealed that the two-residue insertion located between positions 68 and 69 (not between 66 and 67 as previously surmised) extended an existing loop region that effectively increased the surface area adjacent to the first complementarity determining region (CDR1). Further, an unusual interaction between the Arg 25 and Phe 2 residues commonly found in lambda 6 molecules was noted. However, the structures of V lambda 6 Wil and Jto also differed from each other, as evidenced by the presence in the latter of certain ionic and hydrophobic interactions that we posit increased protein stability and thus prevented amyloid formation.

Organizational Affiliation:

Department of Chemistry, Texas A&M University, College Station, Texas 77843, USA.

Macromolecules

Find similar proteins by:

(by identity cutoff) | 3D Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
PROTEIN (BENCE-JONES PROTEIN WIL, A VARIABLE DOMAIN FROM LAMBDA-6 TYPE IMMUNOGLOBULIN LIGHT CHAIN)	A, B	111	Homo sapiens	Mutation(s): 0 Gene Names: IGLV6-57
UniProt & NIH Common Fund Data Resources
Find proteins for P01721 (Homo sapiens) Explore P01721 Go to UniProtKB: P01721
PHAROS: P01721 GTEx: ENSG00000211640
Entity Groups
Sequence Clusters	30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt Group	P01721
Protein Feature View Expand
Reference Sequence